Despite these reports, the only clinical trial that utilizes MEK inhibition in bladder cancer is the ongoing MATCH screening trial in advanced solid tumors (NCT02465060), using mutation status of BRAF, GNA11, and NF1 to identify potential responders to the MEK inhibitor, Trametinib. This evidence concerns the gene BRAF and urinary bladder cancer.